Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350168 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
A Phase 3 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 647
- Enrollment target
- 1
- Study location
NCT00350168: Completed Phase 3 study of Hypertension, sponsored by Novartis.
NCT00350168 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 647 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350168, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 647 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Conditions Studied
Interventions
- DRUG valsartan + amlodipine
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals Corp - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 647 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
What the finished NCT00350168 record still lists
NCT00350168 is an interventional study that assigns participants to a tested intervention. The registered 647 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which valsartan + amlodipine is the first listed.
NCT00350168 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00350168 about?
NCT00350168 is a clinical study titled "Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension". The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
What is the current status of trial NCT00350168?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 647 participants. The study started on 2006-06. Estimated completion is 2007-04.
What conditions does trial NCT00350168 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00350168?
The interventions under investigation include: valsartan + amlodipine (DRUG).
Who is sponsoring clinical trial NCT00350168?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350168 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00350168's enrollment target sits among peer trials
647 97th of 470 higher than 373 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07027306 · 648 participants
The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures
- NCT07164456 · 648 participants · NA
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
- NCT04863222 · 646 participants · Phase 4
Clinical and Radiographic Success of MTA vs Biodentine
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia